It turns out that bacteria could hold a key to transforming how doctors treat disease -- at least that's what Editas, a privately held company that just raised $120 million from investors including Bill Gates, seems to think.
First, a bit of background Editas was founded in 2013 through $43 million in venture funding from the likes of Flagship Ventures and Polaris Partners and the company is researching a fascinating gene-editing technique based on the immune system of bacteria.